First Personal Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

First Personal Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$116	Buy	+1	New	+$137	﹤0.01%	527
2023 Q4	–	Sell	-28	Closed	-$3.15K	–	393
2023 Q3	$3.15K	Hold	28	–	–	﹤0.01%	354
2023 Q2	$2.64K	Hold	28	–	–	﹤0.01%	356
2023 Q1	$2.83K	Hold	28	–	–	﹤0.01%	377
2022 Q4	$3.34K	Hold	28	–	–	﹤0.01%	363
2022 Q3	$3K	Hold	28	–	–	﹤0.01%	402
2022 Q2	$3K	Hold	28	–	–	﹤0.01%	316
2022 Q1	$3K	Buy	+28	New	+$2.37K	﹤0.01%	321
2018 Q2	–	Sell	-606	Closed	-$50K	–	840
2018 Q1	$50K	Sell	606 -152	-20%	-$12.8K	0.01%	435
2017 Q4	$59K	Buy	758 +68	+10%	+$4.64K	0.01%	439
2017 Q3	$42K	Hold	690	–	–	0.01%	461
2017 Q2	$32K	Buy	690 +150	+28%	+$7.28K	0.01%	501
2017 Q1	$23K	Buy	540 +127	+31%	+$5.44K	0.01%	539
2016 Q4	$16K	Buy	+413	New	+$18.7K	﹤0.01%	594
2016 Q3	–	Sell	-19	Closed	-$1K	–	832
2016 Q2	$1K	Buy	+19	New	+$875	﹤0.01%	794

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Personal Financial Services's NBIX Position: Q3 2024 in Review

First Personal Financial Services opened a new position in Neurocrine Biosciences (NBIX) in Q3 2024: 1 share worth $116. The stake represents ﹤0.01% of the portfolio and ranks #527 among its holdings. This is a return to the name: First Personal Financial Services previously reported a position in NBIX as recently as Q3 2023.

First Personal Financial Services first reported a position in NBIX in Q2 2016 and has held it in 15 quarters since. The position peaked at $59K in Q4 2017. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

First Personal Financial Services held 1 share of Neurocrine Biosciences worth $116 as of Q3 2024.
Neurocrine Biosciences was a new First Personal Financial Services position in Q3 2024.
Neurocrine Biosciences made up ﹤0.01% of First Personal Financial Services's portfolio in Q3 2024, its #527 holding.
First Personal Financial Services first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 15 quarters since.
First Personal Financial Services's Neurocrine Biosciences position peaked at $59K in Q4 2017.
574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on First Personal Financial Services's 13F filing for Q3 2024, filed 1 Nov 2024.